Related Experiment Videos
Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
P A Philip1, L D Lewis, C A James
1Department of Clinical Pharmacology, United Medical School, Guy's Hospital, London Bridge, U.K.
Cancer Chemotherapy and Pharmacology
|January 1, 1988
Summary
This study investigated if ifosfamide (IF) drug clearance and activity in patients correlate with debrisoquine oxidation. Results show no link between debrisoquine metabolic ratio and IF pharmacokinetics or alkylating activity.
Area of Science:
- Pharmacology
- Oncology
- Clinical Chemistry
Background:
- Ifosfamide (IF) is a crucial chemotherapeutic agent.
- Understanding IF pharmacokinetics is vital for optimizing cancer treatment.
- Debrisoquine oxidation is a known metabolic pathway influencing drug clearance.
Purpose of the Study:
- To determine ifosfamide (IF) pharmacokinetics and plasma alkylating activity.
- To investigate the correlation between debrisoquine metabolic ratio (DMR) and IF pharmacokinetics.
- To assess the relationship between DMR and plasma NBP-alkylating activity.
Main Methods:
- Pharmacokinetic analysis of IF in 33 cancer patients.
- Measurement of plasma NBP-alkylating activity post-IF administration.
- Phenotyping of subjects based on debrisoquine oxidation (DMR).
Main Results:
- No correlation was found between DMR and total plasma clearance of IF (CLIF).
- No correlation was observed between DMR and the AUC of plasma NBP-alkylating activity.
- Individual variability in IF metabolism and activity is not explained by debrisoquine oxidation status.
Conclusions:
- Debrisoquine oxidation status does not predict ifosfamide pharmacokinetics or activity.
- The debrisoquine metabolic ratio is not a reliable biomarker for IF therapy individualization.
- Further research is needed to identify factors influencing IF variability in patients.